Showing posts with label myriad genetics. Show all posts
Showing posts with label myriad genetics. Show all posts
Wednesday, May 09, 2012
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0
Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. OncologyMAP® v. 2.0 is a comprehensive, cost-effective testing service that builds on the success of the original OncologyMAP® service by increasing the scope and diversity of biomarker analysis for drug re-tasking, indication expansion, and patient stratification studies and provides researchers with the ability to accelerate the pace of discovery, validation, and translation of cancer biomarkers into clinically useful tests......................
add your opinions
biomarkers
,
Myriad
,
myriad genetics
,
NCI
,
OncologyMAP
,
patents
Subscribe to:
Posts
(
Atom
)